JP2004517048A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517048A5 JP2004517048A5 JP2002523888A JP2002523888A JP2004517048A5 JP 2004517048 A5 JP2004517048 A5 JP 2004517048A5 JP 2002523888 A JP2002523888 A JP 2002523888A JP 2002523888 A JP2002523888 A JP 2002523888A JP 2004517048 A5 JP2004517048 A5 JP 2004517048A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- oxo
- group
- fluorophenyl
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 2-oxo-morpholin-4-yl group Chemical group 0.000 description 71
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 35
- 150000001875 compounds Chemical class 0.000 description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000001352 cyclobutyloxy group Chemical group C1(CCC1)O* 0.000 description 5
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- KMIVCBCOKOZZRN-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(5-methyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 KMIVCBCOKOZZRN-UHFFFAOYSA-N 0.000 description 5
- ONOWKYWJTZDNCT-MRXNPFEDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[(3r)-3-methyl-2-oxomorpholin-4-yl]but-2-enamide Chemical compound C1COC(=O)[C@@H](C)N1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ONOWKYWJTZDNCT-MRXNPFEDSA-N 0.000 description 5
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- GOEZUUHXYGDNCD-GOSISDBHSA-N ethyl (2r)-2-[[4-[[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]amino]-4-oxobut-2-enyl]-(2-hydroxyethyl)amino]propanoate Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CCO)[C@H](C)C(=O)OCC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 GOEZUUHXYGDNCD-GOSISDBHSA-N 0.000 description 3
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- CCOKBACMAWRBJZ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(2-methyl-6-oxomorpholin-4-yl)but-2-enamide Chemical compound C1C(=O)OC(C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 CCOKBACMAWRBJZ-UHFFFAOYSA-N 0.000 description 3
- ONOWKYWJTZDNCT-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(3-methyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound C1COC(=O)C(C)N1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ONOWKYWJTZDNCT-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- MQPOXBYCYDBMJH-UHFFFAOYSA-N 2-[[4-[[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]amino]-4-oxobut-2-enyl]-(2-hydroxyethyl)amino]acetic acid Chemical compound C=12C=C(NC(=O)C=CCN(CCO)CC(O)=O)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 MQPOXBYCYDBMJH-UHFFFAOYSA-N 0.000 description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 2
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000062 cyclohexylmethoxy group Chemical group [H]C([H])(O*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- XWSRRYNPCDAWKP-UHFFFAOYSA-N ethyl 2-[[4-[[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]amino]-4-oxobut-2-enyl]-(2-hydroxy-2-methylpropyl)amino]acetate Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CC(=O)OCC)CC(C)(C)O)=CC2=C1NC1=CC=C(F)C(Cl)=C1 XWSRRYNPCDAWKP-UHFFFAOYSA-N 0.000 description 2
- OQFKTDPRJBLWPS-UHFFFAOYSA-N ethyl 2-[[4-[[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]amino]-4-oxobut-2-enyl]-(2-hydroxyethyl)amino]acetate Chemical compound N1=CN=C2C=C(OCC3CC3)C(NC(=O)C=CCN(CCO)CC(=O)OCC)=CC2=C1NC1=CC=C(F)C(Cl)=C1 OQFKTDPRJBLWPS-UHFFFAOYSA-N 0.000 description 2
- SEOUETYTEUFQGQ-UHFFFAOYSA-N n-[4-(3-bromoanilino)-7-methoxyquinazolin-6-yl]-4-(2-oxomorpholin-4-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3CC(=O)OCC3)C(OC)=CC2=NC=NC=1NC1=CC=CC(Br)=C1 SEOUETYTEUFQGQ-UHFFFAOYSA-N 0.000 description 2
- SMCDHGJQIQUNIM-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(2,2-dimethyl-6-oxomorpholin-4-yl)but-2-enamide Chemical compound C1C(=O)OC(C)(C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 SMCDHGJQIQUNIM-UHFFFAOYSA-N 0.000 description 2
- ZOOUDMWPZJXWEZ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ZOOUDMWPZJXWEZ-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 0 *c1cc2ncnc(NI=*)c2cc1N Chemical compound *c1cc2ncnc(NI=*)c2cc1N 0.000 description 1
- HTWMYCGEXASIGG-GOSISDBHSA-N 4-(5,5-dimethyl-2-oxomorpholin-4-yl)-n-[4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]but-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=C2)=NC=NC1=CC=C2NC(=O)C=CCN1CC(=O)OCC1(C)C HTWMYCGEXASIGG-GOSISDBHSA-N 0.000 description 1
- WLCDWQKCHZPMLJ-ZWKOTPCHSA-N 4-[(2s)-2-methyl-6-oxomorpholin-4-yl]-n-[4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]but-2-enamide Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C1=C2)=NC=NC1=CC=C2NC(=O)C=CCN1C[C@H](C)OC(=O)C1 WLCDWQKCHZPMLJ-ZWKOTPCHSA-N 0.000 description 1
- YHDXPFVJAIHRAS-WMZOPIPTSA-N N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-[(2S)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YHDXPFVJAIHRAS-WMZOPIPTSA-N 0.000 description 1
- LLRDMIKQIZFZHD-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-yl]-4-(2-ethyl-6-oxomorpholin-4-yl)but-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN1CC(OC(C1)CC)=O)=O)C1CC1)OC LLRDMIKQIZFZHD-UHFFFAOYSA-N 0.000 description 1
- CYGNAHMCEHQYRZ-UHFFFAOYSA-N N-[4-(3-chloro-4-fluoroanilino)-7-cyclopropyl-2-methoxyquinazolin-6-yl]-4-(2-oxomorpholin-4-yl)but-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN1CC(OCC1)=O)=O)C1CC1)OC CYGNAHMCEHQYRZ-UHFFFAOYSA-N 0.000 description 1
- RWXILWHGFPAHPO-LJQANCHMSA-N N-[7-cyclopropyl-2-methoxy-4-[[(1R)-1-phenylethyl]amino]quinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound C1(=CC=CC=C1)[C@@H](C)NC1=NC(=NC2=CC(=C(C=C12)NC(C=CCN1CC(OCC1(C)C)=O)=O)C1CC1)OC RWXILWHGFPAHPO-LJQANCHMSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- VMDRYOBNPDPEFY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(2-methoxyethoxy)quinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3C(COC(=O)C3)(C)C)C(OCCOC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 VMDRYOBNPDPEFY-UHFFFAOYSA-N 0.000 description 1
- PJUPDYXOPGQSMN-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-(2-oxomorpholin-4-yl)but-2-enamide Chemical compound C1=C(Cl)C(F)=CC=C1NC(C1=C2)=NC=NC1=CC(OCC1CC1)=C2NC(=O)C=CCN1CC(=O)OCC1 PJUPDYXOPGQSMN-UHFFFAOYSA-N 0.000 description 1
- CCOKBACMAWRBJZ-MRXNPFEDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[(2r)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 CCOKBACMAWRBJZ-MRXNPFEDSA-N 0.000 description 1
- CCOKBACMAWRBJZ-INIZCTEOSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[(2s)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 CCOKBACMAWRBJZ-INIZCTEOSA-N 0.000 description 1
- ONOWKYWJTZDNCT-INIZCTEOSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[(3s)-3-methyl-2-oxomorpholin-4-yl]but-2-enamide Chemical compound C1COC(=O)[C@H](C)N1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 ONOWKYWJTZDNCT-INIZCTEOSA-N 0.000 description 1
- PCJFYVJPOFXARK-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(cyclopropylmethoxy)quinazolin-6-yl]-4-[1,3-dioxolan-2-ylmethyl(methyl)amino]but-2-enamide Chemical compound O1CCOC1CN(C)CC=CC(=O)NC(C(=CC1=NC=N2)OCC3CC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 PCJFYVJPOFXARK-UHFFFAOYSA-N 0.000 description 1
- HBJJUSHREJSZCK-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxan-4-yloxy)quinazolin-6-yl]-4-(2,2-dimethyl-6-oxomorpholin-4-yl)but-2-enamide Chemical compound C1C(=O)OC(C)(C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCOCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 HBJJUSHREJSZCK-UHFFFAOYSA-N 0.000 description 1
- MZZRGWDBGCKNCG-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxan-4-yloxy)quinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCOCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 MZZRGWDBGCKNCG-UHFFFAOYSA-N 0.000 description 1
- NCLFLVTUXADXQE-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-(oxolan-2-ylmethoxy)quinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OCC3OCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 NCLFLVTUXADXQE-UHFFFAOYSA-N 0.000 description 1
- YWGCPWOZUWEHGA-GOSISDBHSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YWGCPWOZUWEHGA-GOSISDBHSA-N 0.000 description 1
- YHDXPFVJAIHRAS-SJLPKXTDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]-4-[(2r)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YHDXPFVJAIHRAS-SJLPKXTDSA-N 0.000 description 1
- YHDXPFVJAIHRAS-FUHWJXTLSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3r)-oxolan-3-yl]oxyquinazolin-6-yl]-4-[(2s)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YHDXPFVJAIHRAS-FUHWJXTLSA-N 0.000 description 1
- YWGCPWOZUWEHGA-SFHVURJKSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3s)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YWGCPWOZUWEHGA-SFHVURJKSA-N 0.000 description 1
- YHDXPFVJAIHRAS-AEFFLSMTSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(3s)-oxolan-3-yl]oxyquinazolin-6-yl]-4-[(2r)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)O[C@@H]3COCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YHDXPFVJAIHRAS-AEFFLSMTSA-N 0.000 description 1
- YATAUUBWSCHJNQ-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 YATAUUBWSCHJNQ-UHFFFAOYSA-N 0.000 description 1
- WVKDOGWQTANXMX-MRXNPFEDSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-[(2r)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 WVKDOGWQTANXMX-MRXNPFEDSA-N 0.000 description 1
- WVKDOGWQTANXMX-INIZCTEOSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclobutyloxyquinazolin-6-yl]-4-[(2s)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@@H](C)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 WVKDOGWQTANXMX-INIZCTEOSA-N 0.000 description 1
- RHQSWQLBVJZSIR-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-cyclopentyloxyquinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound CC1(C)COC(=O)CN1CC=CC(=O)NC(C(=CC1=NC=N2)OC3CCCC3)=CC1=C2NC1=CC=C(F)C(Cl)=C1 RHQSWQLBVJZSIR-UHFFFAOYSA-N 0.000 description 1
- SJNPYHNHNFJXCY-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(5,5-dimethyl-2-oxomorpholin-4-yl)but-2-enamide Chemical compound C=12C=C(NC(=O)C=CCN3C(COC(=O)C3)(C)C)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 SJNPYHNHNFJXCY-UHFFFAOYSA-N 0.000 description 1
- YDTSPMQRCGKWRK-CQSZACIVSA-N n-[4-(3-chloro-4-fluoroanilino)quinazolin-6-yl]-4-[(2r)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1C(=O)O[C@H](C)CN1CC=CC(=O)NC1=CC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=C1 YDTSPMQRCGKWRK-CQSZACIVSA-N 0.000 description 1
- WOWRAEPIBQSHBM-ZWKOTPCHSA-N n-[7-methoxy-4-[[(1r)-1-phenylethyl]amino]quinazolin-6-yl]-4-[(2s)-2-methyl-6-oxomorpholin-4-yl]but-2-enamide Chemical compound C1([C@@H](C)NC=2N=CN=C3C=C(C(=CC3=2)NC(=O)C=CCN2CC(=O)O[C@@H](C)C2)OC)=CC=CC=C1 WOWRAEPIBQSHBM-ZWKOTPCHSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10042060A DE10042060A1 (de) | 2000-08-26 | 2000-08-26 | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| PCT/EP2001/009537 WO2002018373A1 (de) | 2000-08-26 | 2001-08-18 | Chinazolin derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004517048A JP2004517048A (ja) | 2004-06-10 |
| JP2004517048A5 true JP2004517048A5 (enExample) | 2008-10-09 |
Family
ID=7653947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002523888A Pending JP2004517048A (ja) | 2000-08-26 | 2001-08-18 | キナゾリン誘導体、これらの化合物を含む医薬組成物、それらの使用及びそれらの調製方法 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1315717A1 (enExample) |
| JP (1) | JP2004517048A (enExample) |
| AU (1) | AU2001284021A1 (enExample) |
| CA (1) | CA2417050C (enExample) |
| DE (1) | DE10042060A1 (enExample) |
| MX (1) | MXPA03000873A (enExample) |
| WO (1) | WO2002018373A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078735A1 (de) | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
| US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
| DE10221018A1 (de) * | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| US7223749B2 (en) | 2003-02-20 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| DE10307165A1 (de) * | 2003-02-20 | 2004-09-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung |
| GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
| US7569577B2 (en) | 2003-09-16 | 2009-08-04 | Astrazeneca Ab | Quinazoline derivatives as tyrosine kinase inhibitors |
| JP4036885B2 (ja) | 2003-09-19 | 2008-01-23 | アストラゼネカ アクチボラグ | キナゾリン誘導体 |
| JP4934432B2 (ja) | 2004-02-19 | 2012-05-16 | レクサン ファーマシューティカルズ インコーポレイテッド | キナゾリン誘導体およびキナゾリン誘導体の治療への使用 |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1856095B1 (en) | 2005-02-26 | 2011-08-24 | AstraZeneca AB | Quinazoline derivatives as tyrosine kinase inhibitors |
| WO2007055513A1 (en) * | 2005-11-08 | 2007-05-18 | Hanmi Pharm. Co., Ltd. | Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof |
| KR100832593B1 (ko) * | 2005-11-08 | 2008-05-27 | 한미약품 주식회사 | 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법 |
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| SI2068880T1 (sl) | 2006-09-18 | 2012-08-31 | Boehringer Ingelheim Int | Postopek za zdravljenje raka, ki vsebuje mutacije EGFR |
| EP1921070A1 (de) | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung |
| EA200901041A1 (ru) | 2007-02-06 | 2010-02-26 | Бёрингер Ингельхайм Интернациональ Гмбх | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения |
| RS52573B (sr) | 2008-02-07 | 2013-04-30 | Boehringer Ingelheim International Gmbh | Spirociklični heterocikli, lekovi koji sadrže navedeno jedinjenje, njihova primena i postupak za njihovu proizvodnju |
| BRPI0912170A2 (pt) | 2008-05-13 | 2015-10-13 | Astrazeneca Ab | composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente |
| CA2733153C (en) | 2008-08-08 | 2016-11-08 | Boehringer Ingelheim International Gmbh | Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them |
| US8507502B2 (en) | 2008-11-10 | 2013-08-13 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| JP5963672B2 (ja) | 2009-07-06 | 2016-08-03 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法 |
| PH12012500097A1 (en) * | 2009-07-21 | 2011-01-27 | Shanghai Inst Organic Chem | Potent small molecule inhibitors of autophagy, and methods of use thereof |
| CN102382106A (zh) * | 2010-08-30 | 2012-03-21 | 黄振华 | 苯胺取代的喹唑啉衍生物 |
| WO2013135176A1 (zh) * | 2012-03-16 | 2013-09-19 | 苏州迈泰生物技术有限公司 | 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| CN108148071B (zh) * | 2016-11-25 | 2019-10-15 | 广东东阳光药业有限公司 | 氨基喹唑啉衍生物的盐及其用途 |
| CN115894455B (zh) * | 2021-09-30 | 2024-04-19 | 北京赛特明强医药科技有限公司 | 一种喹唑啉类化合物、组合物及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW436485B (en) * | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU3281600A (en) * | 1999-02-27 | 2000-09-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transsduction mediated by tyrosine kinases |
| DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| WO2000078735A1 (de) * | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma Kg | Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
| DE19928281A1 (de) * | 1999-06-21 | 2000-12-28 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE10017539A1 (de) * | 2000-04-08 | 2001-10-11 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
-
2000
- 2000-08-26 DE DE10042060A patent/DE10042060A1/de not_active Withdrawn
-
2001
- 2001-08-18 WO PCT/EP2001/009537 patent/WO2002018373A1/de not_active Ceased
- 2001-08-18 MX MXPA03000873A patent/MXPA03000873A/es unknown
- 2001-08-18 CA CA002417050A patent/CA2417050C/en not_active Expired - Fee Related
- 2001-08-18 JP JP2002523888A patent/JP2004517048A/ja active Pending
- 2001-08-18 EP EP01962953A patent/EP1315717A1/de not_active Withdrawn
- 2001-08-18 AU AU2001284021A patent/AU2001284021A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004517048A5 (enExample) | ||
| JP2004516283A5 (enExample) | ||
| JP2005538955A5 (enExample) | ||
| RU2004135064A (ru) | Новые замещенные индолы | |
| IL156277A (en) | Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof | |
| AR033562A1 (es) | Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion | |
| JP4009681B2 (ja) | 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物 | |
| CA2472293C (en) | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | |
| CA2417050C (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| AU2003215678B2 (en) | Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents | |
| JP2012519179A5 (enExample) | ||
| RU2011139321A (ru) | Модулирующие jak киназу хиназолиновые производные и способы их применения | |
| RU2005137403A (ru) | Новые замещенные 3-сера-индолы | |
| JP2005532371A5 (enExample) | ||
| JP2007186518A5 (enExample) | ||
| JP4915715B2 (ja) | フェニルピリダジン誘導体及びこれを含有する医薬 | |
| CN1172484A (zh) | 杂芳环取代的苯基噁唑烷酮抗菌剂 | |
| CA2759063A1 (en) | 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(n,n-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((s)-tetrahydrofuran-3-yloxy)-quinazoline dimaleate and the use thereof | |
| RU2005128826A (ru) | Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения | |
| JP2008520665A5 (enExample) | ||
| MXPA04004982A (es) | Derivados de benzotiazol. | |
| JP2005526123A5 (enExample) | ||
| PT566199E (pt) | 1,2,4-oxadiazolil-fenioxialquilizoxazoles e suas utilizacoes como agentes antivirais | |
| CA2483590A1 (en) | Use of inhibitors of egfr-mediated signal transduction for the treatment of benign prostatic hyperplasia (bph)/prostatic hypertrophy | |
| EP0424244B1 (fr) | Dérivés d'aryl-3 oxazolidinone, leur procédé de préparation et leur application en thérapeutique |